sur OXURION (EBR:OXUR)
Oxurion to Acquire Preclinical Microbiology CRO in Toulouse
Oxurion NV, a biopharmaceutical company, has signed a letter of intent to acquire 70% of a preclinical microbiology company specializing in infectious diseases, dermocosmetics, and nutraceuticals. This acquisition aligns with Oxurion's strategy to diversify its expertise and strengthen its presence in Toulouse.
The target company has been a leader in preclinical services for over a decade, providing research and development services in human and animal infectious diseases. It has also expanded into high-growth sectors like dermocosmetics and nutraceuticals, serving over 140 clients globally.
The acquisition is valued at €750,000. Initial payment will be €525,000, with potential earn-outs based on performance. Oxurion aims to complete the transaction by October 2025, pending due diligence and legal agreements.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de OXURION